BACKGROUND: The current study aims to detect the differential expression of lncRNA UCA1 in serum of patients with gastric cancer and a normal control group and to explore its efficacy and significance in clinical diagnosis of gastric cancer. METHODS: The expression of UCA1 in serum of gastric cancer and normal control group was detected by real-time fluorescence quantitative PCR, and its correlation with clinicopathological characteristics of gastric cancer was analyzed. The diagnostic efficacy of UCA1 in gastric cancer was evaluated by ROC curve and risk score analysis, and compared with carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 72-4 (CA72-4), and alpha fetoprotein. RESULTS: The expression of UCA1 in serum of patients with gastric cancer was significantly higher than that of the normal control group. The expression level was not correlated with age, gender, clinical stage, lymph node metastasis, and distant metastasis, but negatively correlated with the differentiation of cancer cells. The area under the curve of UCA1 in the diagnosis of gastric cancer was 0.759 (95% CI: 0.612 - 0.906). The sensitivity and specificity were 93.20% and 78.63%, respectively. Compared with CA9-9, CEA and CA72-4, the sensitivity of diagnosis increased significantly. CONCLUSIONS: In summary, the high expression of UCA1 in serum of gastric cancer may be a potential biomarker for clinical diagnosis of gastric cancer.
BACKGROUND: The current study aims to detect the differential expression of lncRNA UCA1 in serum of patients with gastric cancer and a normal control group and to explore its efficacy and significance in clinical diagnosis of gastric cancer. METHODS: The expression of UCA1 in serum of gastric cancer and normal control group was detected by real-time fluorescence quantitative PCR, and its correlation with clinicopathological characteristics of gastric cancer was analyzed. The diagnostic efficacy of UCA1 in gastric cancer was evaluated by ROC curve and risk score analysis, and compared with carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 72-4 (CA72-4), and alpha fetoprotein. RESULTS: The expression of UCA1 in serum of patients with gastric cancer was significantly higher than that of the normal control group. The expression level was not correlated with age, gender, clinical stage, lymph node metastasis, and distant metastasis, but negatively correlated with the differentiation of cancer cells. The area under the curve of UCA1 in the diagnosis of gastric cancer was 0.759 (95% CI: 0.612 - 0.906). The sensitivity and specificity were 93.20% and 78.63%, respectively. Compared with CA9-9, CEA and CA72-4, the sensitivity of diagnosis increased significantly. CONCLUSIONS: In summary, the high expression of UCA1 in serum of gastric cancer may be a potential biomarker for clinical diagnosis of gastric cancer.